Andrew Morris
Concepts (451)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lysophospholipids | 15 | 2016 | 34 | 1.860 |
Why?
| Polyisoprenyl Phosphates | 4 | 2014 | 19 | 1.050 |
Why?
| Polychlorinated Biphenyls | 8 | 2018 | 26 | 1.000 |
Why?
| Streptomyces | 9 | 2016 | 10 | 0.890 |
Why?
| Lipid Metabolism | 3 | 2013 | 194 | 0.860 |
Why?
| Sphingosine | 9 | 2015 | 27 | 0.840 |
Why?
| Phosphatidate Phosphatase | 6 | 2018 | 11 | 0.700 |
Why?
| Phosphoric Monoester Hydrolases | 5 | 2015 | 24 | 0.680 |
Why?
| Adipogenesis | 3 | 2018 | 54 | 0.640 |
Why?
| Ceramides | 6 | 2014 | 32 | 0.610 |
Why?
| Phosphoric Diester Hydrolases | 6 | 2016 | 30 | 0.520 |
Why?
| Animals | 44 | 2018 | 14409 | 0.490 |
Why?
| Protein Prenylation | 2 | 2013 | 5 | 0.490 |
Why?
| Mice | 31 | 2018 | 6428 | 0.480 |
Why?
| Farnesol | 1 | 2013 | 3 | 0.470 |
Why?
| Mevalonic Acid | 1 | 2013 | 7 | 0.470 |
Why?
| Diterpenes | 1 | 2013 | 32 | 0.460 |
Why?
| Phosphotransferases (Alcohol Group Acceptor) | 5 | 2014 | 25 | 0.460 |
Why?
| Sesquiterpenes | 2 | 2013 | 91 | 0.450 |
Why?
| Environmental Pollutants | 4 | 2018 | 101 | 0.420 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 150 | 0.410 |
Why?
| Adipocytes | 4 | 2018 | 128 | 0.410 |
Why?
| Sphingolipids | 3 | 2018 | 14 | 0.410 |
Why?
| Glucose | 4 | 2015 | 366 | 0.400 |
Why?
| Enzyme Inhibitors | 5 | 2015 | 446 | 0.400 |
Why?
| Nuclear Localization Signals | 1 | 2010 | 6 | 0.380 |
Why?
| Phosphatidic Acids | 1 | 2010 | 8 | 0.380 |
Why?
| Signal Transduction | 10 | 2016 | 1752 | 0.380 |
Why?
| Mice, Inbred C57BL | 16 | 2016 | 2001 | 0.380 |
Why?
| Molecular Structure | 12 | 2017 | 319 | 0.360 |
Why?
| Endoplasmic Reticulum | 1 | 2010 | 123 | 0.340 |
Why?
| Antifungal Agents | 3 | 2016 | 363 | 0.330 |
Why?
| Nuclear Proteins | 1 | 2010 | 253 | 0.330 |
Why?
| Diet, High-Fat | 4 | 2015 | 216 | 0.330 |
Why?
| Homeostasis | 3 | 2015 | 223 | 0.320 |
Why?
| Membrane Proteins | 3 | 2015 | 389 | 0.320 |
Why?
| Cell Movement | 6 | 2013 | 271 | 0.300 |
Why?
| Methylamines | 2 | 2018 | 16 | 0.300 |
Why?
| Oxazoles | 2 | 2016 | 9 | 0.300 |
Why?
| Anti-Bacterial Agents | 4 | 2016 | 825 | 0.280 |
Why?
| Glycosides | 2 | 2016 | 16 | 0.280 |
Why?
| Oligopeptides | 2 | 2016 | 95 | 0.280 |
Why?
| Multidrug Resistance-Associated Proteins | 2 | 2015 | 19 | 0.270 |
Why?
| Neuroprotective Agents | 2 | 2016 | 125 | 0.270 |
Why?
| Oxidative Stress | 5 | 2015 | 958 | 0.270 |
Why?
| S-Adenosylmethionine | 2 | 2016 | 56 | 0.260 |
Why?
| Glutathione | 3 | 2015 | 330 | 0.260 |
Why?
| Liver | 4 | 2016 | 1226 | 0.260 |
Why?
| Drug Design | 4 | 2015 | 133 | 0.260 |
Why?
| Antibiotics, Antineoplastic | 2 | 2015 | 85 | 0.250 |
Why?
| Aminoglycosides | 2 | 2015 | 22 | 0.250 |
Why?
| Antineoplastic Agents | 1 | 2013 | 1300 | 0.250 |
Why?
| Obesity | 5 | 2018 | 1203 | 0.240 |
Why?
| Phenols | 2 | 2016 | 122 | 0.240 |
Why?
| Peptides, Cyclic | 2 | 2014 | 44 | 0.240 |
Why?
| Sphingomyelin Phosphodiesterase | 2 | 2014 | 10 | 0.240 |
Why?
| Doxorubicin | 2 | 2015 | 259 | 0.240 |
Why?
| Cells, Cultured | 6 | 2013 | 1737 | 0.230 |
Why?
| Endothelial Cells | 4 | 2014 | 294 | 0.230 |
Why?
| Stem Cells | 2 | 2015 | 194 | 0.220 |
Why?
| Neoplasms | 1 | 2013 | 1322 | 0.220 |
Why?
| Focal Adhesions | 2 | 2013 | 12 | 0.220 |
Why?
| Atherosclerosis | 2 | 2016 | 249 | 0.210 |
Why?
| Diet | 2 | 2018 | 598 | 0.210 |
Why?
| Cell Line, Tumor | 7 | 2013 | 1551 | 0.200 |
Why?
| Mice, Knockout | 8 | 2015 | 927 | 0.190 |
Why?
| Myocardial Infarction | 2 | 2015 | 423 | 0.180 |
Why?
| Humans | 31 | 2018 | 54391 | 0.180 |
Why?
| Blood Platelets | 2 | 2012 | 268 | 0.180 |
Why?
| HeLa Cells | 4 | 2016 | 291 | 0.170 |
Why?
| Glucosides | 2 | 2015 | 16 | 0.160 |
Why?
| Dioxins | 1 | 2018 | 8 | 0.160 |
Why?
| Receptors, Aryl Hydrocarbon | 2 | 2015 | 29 | 0.160 |
Why?
| Hematopoietic Stem Cell Mobilization | 2 | 2015 | 61 | 0.160 |
Why?
| Myocardium | 3 | 2015 | 443 | 0.160 |
Why?
| Insulin Resistance | 3 | 2015 | 300 | 0.160 |
Why?
| Peptides | 2 | 2016 | 276 | 0.160 |
Why?
| Up-Regulation | 3 | 2016 | 509 | 0.160 |
Why?
| Curcumin | 1 | 2017 | 19 | 0.150 |
Why?
| Bone Marrow Cells | 2 | 2015 | 232 | 0.150 |
Why?
| Deuterium | 2 | 2016 | 41 | 0.150 |
Why?
| Ethers | 1 | 2016 | 6 | 0.150 |
Why?
| Cell Nucleus | 2 | 2015 | 203 | 0.150 |
Why?
| Naphthoquinones | 2 | 2013 | 14 | 0.150 |
Why?
| Obesity, Morbid | 1 | 2018 | 88 | 0.150 |
Why?
| NF-E2-Related Factor 2 | 3 | 2013 | 63 | 0.150 |
Why?
| Mutation | 2 | 2013 | 1504 | 0.140 |
Why?
| Oxygenases | 1 | 2016 | 10 | 0.140 |
Why?
| Choline | 1 | 2016 | 64 | 0.140 |
Why?
| Steroids | 1 | 2016 | 55 | 0.140 |
Why?
| HEK293 Cells | 5 | 2016 | 245 | 0.140 |
Why?
| Durapatite | 1 | 2015 | 27 | 0.140 |
Why?
| Bile Acids and Salts | 1 | 2016 | 76 | 0.130 |
Why?
| Nuclear Magnetic Resonance, Biomolecular | 4 | 2017 | 34 | 0.130 |
Why?
| Terphenyl Compounds | 1 | 2015 | 1 | 0.130 |
Why?
| Hexuronic Acids | 1 | 2015 | 6 | 0.130 |
Why?
| Uridine | 1 | 2015 | 6 | 0.130 |
Why?
| Dietary Fats | 2 | 2016 | 142 | 0.130 |
Why?
| Lipoprotein Lipase | 1 | 2015 | 15 | 0.130 |
Why?
| Serine C-Palmitoyltransferase | 1 | 2015 | 7 | 0.130 |
Why?
| Drug Carriers | 1 | 2015 | 82 | 0.130 |
Why?
| Tandem Mass Spectrometry | 2 | 2013 | 248 | 0.130 |
Why?
| Multigene Family | 1 | 2015 | 54 | 0.130 |
Why?
| Hematopoietic Stem Cells | 2 | 2014 | 215 | 0.130 |
Why?
| Vancomycin | 1 | 2015 | 88 | 0.130 |
Why?
| Glucuronides | 1 | 2015 | 57 | 0.130 |
Why?
| Myocytes, Smooth Muscle | 2 | 2012 | 92 | 0.130 |
Why?
| Male | 15 | 2018 | 27347 | 0.130 |
Why?
| Pyrrolidonecarboxylic Acid | 1 | 2014 | 1 | 0.130 |
Why?
| Thiazolidines | 1 | 2014 | 6 | 0.130 |
Why?
| Drug Resistance, Bacterial | 1 | 2015 | 81 | 0.130 |
Why?
| Streptomyces antibioticus | 1 | 2014 | 1 | 0.120 |
Why?
| Receptors, Steroid | 1 | 2014 | 21 | 0.120 |
Why?
| RNA, Messenger | 3 | 2014 | 1203 | 0.120 |
Why?
| Osteomyelitis | 1 | 2015 | 124 | 0.120 |
Why?
| Glycosyltransferases | 1 | 2014 | 13 | 0.120 |
Why?
| Methionine Adenosyltransferase | 1 | 2014 | 20 | 0.120 |
Why?
| Carbohydrate Metabolism | 1 | 2014 | 31 | 0.120 |
Why?
| Nucleotides | 1 | 2014 | 23 | 0.120 |
Why?
| Archaeal Proteins | 1 | 2014 | 14 | 0.120 |
Why?
| Sulfolobus solfataricus | 1 | 2014 | 20 | 0.120 |
Why?
| Capillary Permeability | 1 | 2014 | 40 | 0.120 |
Why?
| Weight Loss | 2 | 2015 | 271 | 0.120 |
Why?
| Amines | 1 | 2014 | 46 | 0.120 |
Why?
| Macrolides | 1 | 2013 | 17 | 0.120 |
Why?
| Antioxidants | 2 | 2013 | 297 | 0.120 |
Why?
| Macrophages | 3 | 2014 | 404 | 0.120 |
Why?
| Enzymes | 1 | 2013 | 31 | 0.120 |
Why?
| Cell Proliferation | 3 | 2013 | 1097 | 0.120 |
Why?
| Rifabutin | 1 | 2013 | 5 | 0.120 |
Why?
| Pyrones | 1 | 2013 | 8 | 0.120 |
Why?
| Isocitrate Dehydrogenase | 1 | 2013 | 21 | 0.120 |
Why?
| Actinobacteria | 1 | 2013 | 8 | 0.120 |
Why?
| Benzoxazoles | 1 | 2013 | 12 | 0.120 |
Why?
| Apolipoproteins E | 1 | 2014 | 62 | 0.120 |
Why?
| Hydroxymethylglutaryl CoA Reductases | 1 | 2013 | 10 | 0.120 |
Why?
| Phosphodiesterase Inhibitors | 1 | 2013 | 27 | 0.120 |
Why?
| Rhamnose | 1 | 2013 | 5 | 0.120 |
Why?
| Half-Life | 1 | 2013 | 92 | 0.120 |
Why?
| Benzhydryl Compounds | 1 | 2014 | 75 | 0.120 |
Why?
| Methyltransferases | 1 | 2013 | 29 | 0.120 |
Why?
| Tea | 1 | 2013 | 35 | 0.120 |
Why?
| Inflammation Mediators | 2 | 2014 | 128 | 0.110 |
Why?
| Tissue Distribution | 1 | 2013 | 178 | 0.110 |
Why?
| Central Nervous System Neoplasms | 1 | 2013 | 57 | 0.110 |
Why?
| Stilbenes | 1 | 2013 | 65 | 0.110 |
Why?
| Thionucleosides | 1 | 2012 | 2 | 0.110 |
Why?
| Cysteine | 1 | 2013 | 62 | 0.110 |
Why?
| Antimicrobial Cationic Peptides | 1 | 2013 | 31 | 0.110 |
Why?
| Chromans | 1 | 2013 | 62 | 0.110 |
Why?
| Adenosine Monophosphate | 1 | 2012 | 15 | 0.110 |
Why?
| Ubiquitination | 1 | 2013 | 47 | 0.110 |
Why?
| Anion Transport Proteins | 1 | 2012 | 5 | 0.110 |
Why?
| Receptors, Lipoprotein | 1 | 2012 | 8 | 0.110 |
Why?
| Carotid Artery Injuries | 1 | 2012 | 14 | 0.110 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2014 | 206 | 0.110 |
Why?
| Glioma | 1 | 2013 | 79 | 0.110 |
Why?
| Molecular Sequence Data | 2 | 2015 | 980 | 0.110 |
Why?
| Insulin | 2 | 2013 | 511 | 0.110 |
Why?
| Lymph | 1 | 2012 | 21 | 0.110 |
Why?
| Platelet Activation | 1 | 2012 | 50 | 0.110 |
Why?
| Ubiquitin-Protein Ligases | 1 | 2013 | 100 | 0.110 |
Why?
| Diacylglycerol Kinase | 1 | 2012 | 6 | 0.110 |
Why?
| Human Umbilical Vein Endothelial Cells | 1 | 2013 | 95 | 0.110 |
Why?
| Erucic Acids | 1 | 2012 | 1 | 0.110 |
Why?
| Piperazines | 1 | 2013 | 115 | 0.110 |
Why?
| Adenosine | 1 | 2012 | 71 | 0.110 |
Why?
| Regeneration | 1 | 2013 | 72 | 0.110 |
Why?
| Purinergic P2Y Receptor Antagonists | 1 | 2012 | 30 | 0.110 |
Why?
| Neurites | 1 | 2012 | 17 | 0.110 |
Why?
| Neurogenesis | 1 | 2012 | 30 | 0.110 |
Why?
| ATP-Binding Cassette Transporters | 1 | 2012 | 32 | 0.110 |
Why?
| Axons | 1 | 2012 | 43 | 0.110 |
Why?
| Insulin-Secreting Cells | 1 | 2012 | 23 | 0.110 |
Why?
| Glucose Intolerance | 1 | 2012 | 28 | 0.110 |
Why?
| Protein Phosphatase 1 | 1 | 2011 | 6 | 0.110 |
Why?
| RNA Precursors | 1 | 2011 | 11 | 0.110 |
Why?
| Pyridinium Compounds | 1 | 2011 | 17 | 0.110 |
Why?
| Hematocrit | 1 | 2011 | 51 | 0.100 |
Why?
| Hepatocytes | 1 | 2013 | 214 | 0.100 |
Why?
| Adipose Tissue, Brown | 1 | 2012 | 45 | 0.100 |
Why?
| Protein Binding | 4 | 2016 | 736 | 0.100 |
Why?
| Muscle, Smooth, Vascular | 1 | 2012 | 140 | 0.100 |
Why?
| Integrins | 1 | 2011 | 36 | 0.100 |
Why?
| Alternative Splicing | 1 | 2011 | 64 | 0.100 |
Why?
| Fibroblasts | 2 | 2012 | 386 | 0.100 |
Why?
| Autophagy | 1 | 2013 | 202 | 0.100 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2013 | 251 | 0.100 |
Why?
| Heme Oxygenase-1 | 1 | 2011 | 21 | 0.100 |
Why?
| Caveolin 1 | 1 | 2011 | 22 | 0.100 |
Why?
| Erythrocyte Transfusion | 1 | 2011 | 74 | 0.100 |
Why?
| Catechin | 1 | 2011 | 30 | 0.100 |
Why?
| Anemia | 1 | 2011 | 83 | 0.100 |
Why?
| Eicosapentaenoic Acid | 1 | 2010 | 19 | 0.100 |
Why?
| Platelet Aggregation Inhibitors | 1 | 2012 | 179 | 0.100 |
Why?
| Phenotype | 4 | 2015 | 819 | 0.100 |
Why?
| Docosahexaenoic Acids | 1 | 2010 | 29 | 0.100 |
Why?
| alpha Karyopherins | 1 | 2010 | 1 | 0.100 |
Why?
| Phospholipase D | 1 | 2010 | 5 | 0.100 |
Why?
| Lipoproteins, LDL | 1 | 2012 | 195 | 0.100 |
Why?
| Active Transport, Cell Nucleus | 1 | 2010 | 45 | 0.090 |
Why?
| Amidines | 1 | 2010 | 8 | 0.090 |
Why?
| Liposomes | 1 | 2010 | 53 | 0.090 |
Why?
| Group V Phospholipases A2 | 1 | 2010 | 1 | 0.090 |
Why?
| Membrane Lipids | 1 | 2010 | 15 | 0.090 |
Why?
| rho GTP-Binding Proteins | 1 | 2010 | 6 | 0.090 |
Why?
| Sequence Alignment | 1 | 2010 | 146 | 0.090 |
Why?
| Exercise | 1 | 2015 | 552 | 0.090 |
Why?
| Macrophage Activation | 1 | 2010 | 29 | 0.090 |
Why?
| Cholesterol, LDL | 1 | 2010 | 41 | 0.090 |
Why?
| Cerebellum | 1 | 2011 | 142 | 0.090 |
Why?
| Recombinant Fusion Proteins | 1 | 2010 | 206 | 0.090 |
Why?
| Colonic Neoplasms | 1 | 2011 | 164 | 0.090 |
Why?
| Mice, Inbred BALB C | 1 | 2010 | 370 | 0.090 |
Why?
| Astrocytes | 1 | 2011 | 142 | 0.090 |
Why?
| Kinetics | 3 | 2016 | 692 | 0.090 |
Why?
| Hydrolysis | 3 | 2016 | 68 | 0.090 |
Why?
| Inflammation | 1 | 2014 | 678 | 0.090 |
Why?
| Cardiovascular Diseases | 1 | 2015 | 476 | 0.090 |
Why?
| Boronic Acids | 1 | 2010 | 197 | 0.090 |
Why?
| Magnetic Resonance Spectroscopy | 3 | 2015 | 255 | 0.080 |
Why?
| Models, Molecular | 3 | 2016 | 423 | 0.080 |
Why?
| Catalysis | 3 | 2014 | 98 | 0.080 |
Why?
| Amino Acid Sequence | 1 | 2010 | 767 | 0.080 |
Why?
| Colorectal Neoplasms | 1 | 2012 | 237 | 0.080 |
Why?
| Aging | 1 | 2014 | 784 | 0.080 |
Why?
| Substrate Specificity | 3 | 2014 | 209 | 0.080 |
Why?
| Neurons | 1 | 2012 | 486 | 0.080 |
Why?
| Interleukin-6 | 1 | 2010 | 315 | 0.080 |
Why?
| RNA, Small Interfering | 3 | 2015 | 253 | 0.080 |
Why?
| Protein Structure, Tertiary | 3 | 2016 | 289 | 0.080 |
Why?
| CHO Cells | 3 | 2013 | 123 | 0.080 |
Why?
| Cricetinae | 3 | 2013 | 209 | 0.080 |
Why?
| Hematopoietic Stem Cell Transplantation | 1 | 2013 | 583 | 0.080 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2010 | 435 | 0.080 |
Why?
| Mice, Transgenic | 3 | 2015 | 658 | 0.080 |
Why?
| Rats | 4 | 2016 | 3419 | 0.080 |
Why?
| Phosphorylation | 3 | 2015 | 613 | 0.080 |
Why?
| Structure-Activity Relationship | 3 | 2014 | 423 | 0.080 |
Why?
| Cell Differentiation | 1 | 2010 | 720 | 0.080 |
Why?
| Adipose Tissue | 3 | 2013 | 208 | 0.070 |
Why?
| Glutathione Disulfide | 2 | 2015 | 45 | 0.070 |
Why?
| Appalachian Region | 2 | 2016 | 11 | 0.070 |
Why?
| Receptors, Lysophosphatidic Acid | 2 | 2016 | 4 | 0.070 |
Why?
| Crystallography, X-Ray | 2 | 2016 | 178 | 0.060 |
Why?
| Disease Models, Animal | 3 | 2015 | 1647 | 0.060 |
Why?
| Chromatography, High Pressure Liquid | 2 | 2017 | 377 | 0.060 |
Why?
| Catalytic Domain | 2 | 2014 | 61 | 0.060 |
Why?
| Random Allocation | 2 | 2016 | 312 | 0.060 |
Why?
| Spectrometry, Mass, Electrospray Ionization | 2 | 2013 | 67 | 0.060 |
Why?
| Receptors, Lysosphingolipid | 2 | 2013 | 6 | 0.060 |
Why?
| Base Sequence | 2 | 2015 | 719 | 0.060 |
Why?
| Glucose Tolerance Test | 2 | 2013 | 67 | 0.060 |
Why?
| Polymerase Chain Reaction | 2 | 2015 | 531 | 0.060 |
Why?
| Gene Expression Regulation | 3 | 2012 | 1063 | 0.060 |
Why?
| Phosphatidylinositol 4,5-Diphosphate | 2 | 2013 | 10 | 0.050 |
Why?
| NAD(P)H Dehydrogenase (Quinone) | 2 | 2013 | 24 | 0.050 |
Why?
| Cricetulus | 2 | 2013 | 102 | 0.050 |
Why?
| Thiazolidinediones | 2 | 2015 | 95 | 0.050 |
Why?
| Mass Spectrometry | 2 | 2013 | 313 | 0.050 |
Why?
| Platelet Aggregation | 2 | 2012 | 82 | 0.050 |
Why?
| Recombinant Proteins | 2 | 2015 | 570 | 0.050 |
Why?
| Enzyme Activation | 2 | 2012 | 328 | 0.050 |
Why?
| Genotype | 2 | 2014 | 600 | 0.050 |
Why?
| Lipids | 2 | 2014 | 178 | 0.050 |
Why?
| Female | 7 | 2018 | 28471 | 0.050 |
Why?
| Glycoproteins | 2 | 2013 | 132 | 0.050 |
Why?
| Staphylococcus aureus | 2 | 2015 | 363 | 0.050 |
Why?
| Time Factors | 3 | 2012 | 3210 | 0.050 |
Why?
| Fatty Acids | 2 | 2012 | 175 | 0.050 |
Why?
| Blood Glucose | 2 | 2013 | 489 | 0.040 |
Why?
| Cytokines | 2 | 2014 | 677 | 0.040 |
Why?
| Swine | 2 | 2011 | 430 | 0.040 |
Why?
| NF-kappa B | 2 | 2010 | 336 | 0.040 |
Why?
| Apoptosis | 2 | 2015 | 1302 | 0.040 |
Why?
| Acrylates | 1 | 2017 | 4 | 0.040 |
Why?
| Coal | 1 | 2016 | 1 | 0.040 |
Why?
| Glycosylation | 1 | 2016 | 112 | 0.040 |
Why?
| Taurochenodeoxycholic Acid | 1 | 2016 | 1 | 0.040 |
Why?
| Hydroxycholesterols | 1 | 2016 | 9 | 0.040 |
Why?
| Food-Drug Interactions | 1 | 2016 | 13 | 0.040 |
Why?
| Phosphatidylcholines | 1 | 2016 | 33 | 0.040 |
Why?
| Molecular Conformation | 1 | 2016 | 73 | 0.040 |
Why?
| Enzyme Induction | 1 | 2016 | 80 | 0.040 |
Why?
| Debridement | 1 | 2015 | 54 | 0.030 |
Why?
| Leukocyte Count | 1 | 2015 | 77 | 0.030 |
Why?
| Transaldolase | 1 | 2015 | 1 | 0.030 |
Why?
| Uridine Monophosphate | 1 | 2015 | 3 | 0.030 |
Why?
| Systole | 1 | 2015 | 80 | 0.030 |
Why?
| Risk Factors | 2 | 2015 | 3937 | 0.030 |
Why?
| Drug Delivery Systems | 1 | 2017 | 151 | 0.030 |
Why?
| Heme | 1 | 2015 | 24 | 0.030 |
Why?
| Threonine | 1 | 2015 | 17 | 0.030 |
Why?
| Diet, Fat-Restricted | 1 | 2015 | 11 | 0.030 |
Why?
| Open Reading Frames | 1 | 2015 | 55 | 0.030 |
Why?
| Polyethylene Glycols | 1 | 2015 | 107 | 0.030 |
Why?
| Myocardial Contraction | 1 | 2015 | 116 | 0.030 |
Why?
| Lipid Peroxidation | 1 | 2015 | 132 | 0.030 |
Why?
| Bronchi | 1 | 2015 | 51 | 0.030 |
Why?
| Administration, Oral | 1 | 2016 | 461 | 0.030 |
Why?
| Gene Silencing | 1 | 2015 | 129 | 0.030 |
Why?
| Ventricular Dysfunction, Left | 1 | 2015 | 99 | 0.030 |
Why?
| Hep G2 Cells | 1 | 2014 | 46 | 0.030 |
Why?
| Coal Mining | 1 | 2014 | 3 | 0.030 |
Why?
| Brachiocephalic Trunk | 1 | 2014 | 8 | 0.030 |
Why?
| Imidazoles | 1 | 2015 | 143 | 0.030 |
Why?
| Protein Structure, Quaternary | 1 | 2014 | 28 | 0.030 |
Why?
| Nitrophenols | 1 | 2014 | 15 | 0.030 |
Why?
| Protein Engineering | 1 | 2014 | 21 | 0.030 |
Why?
| Amino Acid Motifs | 1 | 2014 | 57 | 0.030 |
Why?
| Biocatalysis | 1 | 2014 | 20 | 0.030 |
Why?
| Receptor, TIE-2 | 1 | 2014 | 18 | 0.030 |
Why?
| 3T3-L1 Cells | 1 | 2013 | 16 | 0.030 |
Why?
| Naphthols | 1 | 2013 | 10 | 0.030 |
Why?
| Integrases | 1 | 2014 | 45 | 0.030 |
Why?
| Cyclization | 1 | 2013 | 6 | 0.030 |
Why?
| Glutarates | 1 | 2013 | 6 | 0.030 |
Why?
| Transgenes | 1 | 2014 | 55 | 0.030 |
Why?
| Carbohydrates | 1 | 2014 | 64 | 0.030 |
Why?
| Stereoisomerism | 1 | 2013 | 106 | 0.030 |
Why?
| Micromonospora | 1 | 2013 | 1 | 0.030 |
Why?
| Enediynes | 1 | 2013 | 1 | 0.030 |
Why?
| Mice, Inbred NOD | 1 | 2013 | 99 | 0.030 |
Why?
| Salmonella enterica | 1 | 2013 | 18 | 0.030 |
Why?
| Talin | 1 | 2013 | 3 | 0.030 |
Why?
| DNA Primers | 1 | 2013 | 225 | 0.030 |
Why?
| Integrin beta Chains | 1 | 2013 | 14 | 0.030 |
Why?
| Chemotactic Factors | 1 | 2013 | 8 | 0.030 |
Why?
| Cathelicidins | 1 | 2013 | 1 | 0.030 |
Why?
| beta-Defensins | 1 | 2013 | 5 | 0.030 |
Why?
| Regenerative Medicine | 1 | 2013 | 9 | 0.030 |
Why?
| Cell Growth Processes | 1 | 2013 | 24 | 0.030 |
Why?
| Motor Activity | 1 | 2015 | 249 | 0.030 |
Why?
| Stress, Physiological | 1 | 2014 | 194 | 0.030 |
Why?
| HSP90 Heat-Shock Proteins | 1 | 2013 | 53 | 0.030 |
Why?
| Superoxide Dismutase | 1 | 2013 | 125 | 0.030 |
Why?
| Receptors, Purinergic P2Y | 1 | 2012 | 3 | 0.030 |
Why?
| Receptors, CXCR4 | 1 | 2013 | 31 | 0.030 |
Why?
| Drug Screening Assays, Antitumor | 1 | 2013 | 142 | 0.030 |
Why?
| Chemokine CXCL12 | 1 | 2013 | 31 | 0.030 |
Why?
| Epithelial Cells | 1 | 2015 | 255 | 0.030 |
Why?
| Epoprostenol | 1 | 2012 | 27 | 0.030 |
Why?
| Adenosine Diphosphate | 1 | 2012 | 23 | 0.030 |
Why?
| Escherichia coli | 1 | 2015 | 250 | 0.030 |
Why?
| Caspases | 1 | 2013 | 146 | 0.030 |
Why?
| Neointima | 1 | 2012 | 10 | 0.030 |
Why?
| Isotope Labeling | 1 | 2013 | 58 | 0.030 |
Why?
| Methionine | 1 | 2014 | 146 | 0.030 |
Why?
| Aorta | 1 | 2014 | 177 | 0.030 |
Why?
| Diet, Atherogenic | 1 | 2012 | 9 | 0.030 |
Why?
| Mice, Obese | 1 | 2012 | 22 | 0.030 |
Why?
| rho-Associated Kinases | 1 | 2012 | 20 | 0.030 |
Why?
| Antigens, CD34 | 1 | 2013 | 80 | 0.030 |
Why?
| Microfilament Proteins | 1 | 2012 | 47 | 0.030 |
Why?
| Mice, Mutant Strains | 1 | 2012 | 84 | 0.030 |
Why?
| Cell Hypoxia | 1 | 2013 | 87 | 0.030 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2013 | 208 | 0.030 |
Why?
| Cell Adhesion Molecules | 1 | 2012 | 87 | 0.030 |
Why?
| Carotid Artery, Common | 1 | 2012 | 43 | 0.030 |
Why?
| Hyperplasia | 1 | 2012 | 107 | 0.030 |
Why?
| Cyclic AMP | 1 | 2012 | 106 | 0.030 |
Why?
| Lysine | 1 | 2013 | 102 | 0.030 |
Why?
| Embryonic Stem Cells | 1 | 2012 | 17 | 0.030 |
Why?
| Adipokines | 1 | 2012 | 12 | 0.030 |
Why?
| Microbial Sensitivity Tests | 1 | 2013 | 290 | 0.030 |
Why?
| Insulinoma | 1 | 2012 | 7 | 0.030 |
Why?
| Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 101 | 0.030 |
Why?
| Cross-Sectional Studies | 1 | 2018 | 1696 | 0.030 |
Why?
| Staphylococcal Infections | 1 | 2015 | 302 | 0.030 |
Why?
| Neoplasm Metastasis | 1 | 2013 | 252 | 0.030 |
Why?
| Subcutaneous Fat | 1 | 2012 | 19 | 0.030 |
Why?
| Embryo, Mammalian | 1 | 2012 | 69 | 0.030 |
Why?
| Paxillin | 1 | 2012 | 7 | 0.030 |
Why?
| Oncogene Protein v-akt | 1 | 2012 | 11 | 0.030 |
Why?
| Injections, Intraperitoneal | 1 | 2012 | 59 | 0.030 |
Why?
| Gene Expression | 1 | 2015 | 664 | 0.030 |
Why?
| Focal Adhesion Kinase 1 | 1 | 2012 | 15 | 0.030 |
Why?
| Lyases | 1 | 2011 | 2 | 0.030 |
Why?
| Phosphoproteins | 1 | 2012 | 116 | 0.030 |
Why?
| Blood Vessels | 1 | 2012 | 78 | 0.030 |
Why?
| Neoplasm Invasiveness | 1 | 2013 | 294 | 0.030 |
Why?
| Saccharomyces cerevisiae | 1 | 2013 | 218 | 0.030 |
Why?
| Lipogenesis | 1 | 2012 | 34 | 0.030 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2012 | 176 | 0.030 |
Why?
| Proto-Oncogene Proteins c-met | 1 | 2012 | 21 | 0.030 |
Why?
| Vinculin | 1 | 2011 | 3 | 0.030 |
Why?
| Lipoproteins, HDL | 1 | 2011 | 21 | 0.030 |
Why?
| Gene Expression Regulation, Bacterial | 1 | 2014 | 246 | 0.030 |
Why?
| Dyslipidemias | 1 | 2012 | 40 | 0.030 |
Why?
| Blood Preservation | 1 | 2011 | 29 | 0.030 |
Why?
| Disease Susceptibility | 1 | 2012 | 95 | 0.030 |
Why?
| HCT116 Cells | 1 | 2011 | 27 | 0.030 |
Why?
| Bone and Bones | 1 | 2015 | 515 | 0.030 |
Why?
| Transfection | 1 | 2012 | 399 | 0.030 |
Why?
| Ion Channels | 1 | 2012 | 75 | 0.030 |
Why?
| Gene Knockdown Techniques | 1 | 2012 | 125 | 0.030 |
Why?
| Exons | 1 | 2011 | 105 | 0.030 |
Why?
| Lymphocytes | 1 | 2012 | 168 | 0.030 |
Why?
| Myocardial Ischemia | 1 | 2013 | 127 | 0.030 |
Why?
| Fibronectins | 1 | 2011 | 41 | 0.030 |
Why?
| Antigens, CD | 1 | 2013 | 242 | 0.030 |
Why?
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2011 | 34 | 0.030 |
Why?
| Erythrocytes | 1 | 2011 | 98 | 0.030 |
Why?
| Caveolae | 1 | 2011 | 7 | 0.030 |
Why?
| Xenograft Model Antitumor Assays | 1 | 2012 | 219 | 0.020 |
Why?
| Prospective Studies | 1 | 2018 | 2606 | 0.020 |
Why?
| Mice, Nude | 1 | 2012 | 284 | 0.020 |
Why?
| Cell Survival | 1 | 2013 | 657 | 0.020 |
Why?
| Mitochondrial Proteins | 1 | 2012 | 121 | 0.020 |
Why?
| Rotarod Performance Test | 1 | 2011 | 10 | 0.020 |
Why?
| Promoter Regions, Genetic | 1 | 2014 | 520 | 0.020 |
Why?
| Neuroprostanes | 1 | 2010 | 1 | 0.020 |
Why?
| Borohydrides | 1 | 2010 | 2 | 0.020 |
Why?
| Cell Adhesion | 1 | 2011 | 171 | 0.020 |
Why?
| Asthma | 1 | 2015 | 293 | 0.020 |
Why?
| Bilirubin | 1 | 2011 | 49 | 0.020 |
Why?
| Organ Culture Techniques | 1 | 2011 | 53 | 0.020 |
Why?
| Cyclopentanes | 1 | 2010 | 14 | 0.020 |
Why?
| In Situ Nick-End Labeling | 1 | 2011 | 64 | 0.020 |
Why?
| Motor Skills | 1 | 2011 | 31 | 0.020 |
Why?
| Cytoprotection | 1 | 2010 | 48 | 0.020 |
Why?
| Fatty Liver | 1 | 2012 | 129 | 0.020 |
Why?
| Superoxides | 1 | 2010 | 61 | 0.020 |
Why?
| RNA-Binding Proteins | 1 | 2011 | 136 | 0.020 |
Why?
| Binding Sites | 1 | 2011 | 440 | 0.020 |
Why?
| Cell Count | 1 | 2011 | 181 | 0.020 |
Why?
| Phosphodiesterase I | 1 | 2010 | 1 | 0.020 |
Why?
| Dose-Response Relationship, Drug | 1 | 2014 | 1476 | 0.020 |
Why?
| Pyrophosphatases | 1 | 2010 | 13 | 0.020 |
Why?
| Oxadiazoles | 1 | 2010 | 13 | 0.020 |
Why?
| Down-Regulation | 1 | 2012 | 388 | 0.020 |
Why?
| Lymph Nodes | 1 | 2012 | 284 | 0.020 |
Why?
| Lipolysis | 1 | 2010 | 11 | 0.020 |
Why?
| Multienzyme Complexes | 1 | 2010 | 41 | 0.020 |
Why?
| Inhibitory Concentration 50 | 1 | 2010 | 80 | 0.020 |
Why?
| COS Cells | 1 | 2010 | 78 | 0.020 |
Why?
| Cell Membrane | 1 | 2011 | 279 | 0.020 |
Why?
| Albumins | 1 | 2010 | 39 | 0.020 |
Why?
| Cell Line | 1 | 2013 | 1152 | 0.020 |
Why?
| Drug Evaluation, Preclinical | 1 | 2010 | 158 | 0.020 |
Why?
| Protein Transport | 1 | 2010 | 195 | 0.020 |
Why?
| Oxidation-Reduction | 1 | 2010 | 383 | 0.020 |
Why?
| Risk Assessment | 1 | 2014 | 1362 | 0.020 |
Why?
| Endothelium, Vascular | 1 | 2011 | 288 | 0.020 |
Why?
| Pancreatic Neoplasms | 1 | 2012 | 234 | 0.020 |
Why?
| Liver Neoplasms | 1 | 2012 | 352 | 0.020 |
Why?
| Immunohistochemistry | 1 | 2011 | 1090 | 0.020 |
Why?
| Lung Neoplasms | 1 | 2013 | 643 | 0.020 |
Why?
| Aged | 1 | 2011 | 10060 | 0.010 |
Why?
| Middle Aged | 1 | 2011 | 13082 | 0.010 |
Why?
| Adult | 1 | 2011 | 14207 | 0.010 |
Why?
|
|
Morris's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|